Therapeutic Response

FOLR1 positive status confers therapeutic sensitivity to Mirvetuximab soravtansine in patients with Peritoneal Serous Carcinoma.

Statements

Source and description
Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.
Elahere (mirvetuximab soravtansine) [product information]. EMA. The European Medicines Agency (EMA) has authorized mirvetuximab soravtansine for the treatment of adult patients with with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.